Familial hypercholesterolaemia: A review with emphasis on evidence for treatment, new models of care and health economic evaluations

International Journal of Evidence-Based Healthcare

Volumn 10, Issue 3, 2012, Pages 211-221

  Watts, Gerald F ^a   Juniper, Amanda ^a   van Bockxmeer, Frank ^a,b   Ademi, Zanfina ^e   Liew, Danny ^e   O'Leary, Peter ^b,c,d  

^a ROYAL PERTH HOSPITAL   (Australia)

^b School of Pathology and Laboratory Medicine   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Detection; Evidence; Familial hypercholesterolaemia; Health economic evaluation; Model of care; Treatment

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; BLOOD; COST BENEFIT ANALYSIS; DIET; ECONOMICS; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; PATHOPHYSIOLOGY;

APOLIPOPROTEINS B; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DIET; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS;

EID: 84867968213     PISSN: 17441595     EISSN: 17441609     Source Type: Journal    
DOI: 10.1111/j.1744-1609.2012.00272.x     Document Type: Article

References (76)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolaemia: a HuGE prevalence review. Am J Epidemiol 2004; 160: 407-20.
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004; 160: 421-9.
3. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. Br Med J 2000; 321: 148.
4. Pijlman AH, Huijgen R, Verhagen SN et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 2010; 209: 189-94.
5. Bates TR, Burnett JR, van Bockxmeer FM, Hamilton S, Arnolda L, Watts GF. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ 2008; 17: 411-3.
6. National Institute for Health and Clinical Excellence, The National Collaborating Centre for Primary Care. NICE clinical guideline 71: identification and management of familial hypercholesterolaemia. 2008 [2011]. Accessed 10 October 2011. Available from: http://www.nice.org.uk/nicemedia/pdf/ CG071NICEGuideline.pdf
7. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolaemia. Atherosclerosis 2004; 173: 55-68.
8. Watts GF, Sullivan DR, Poplawski N et al. Familial hypercholesterolaemia: a model of care for Australasia. Atherosclerosis Supplements 2011; 12: 221-63.
9. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: 133-40.
10. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-25.
11. Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14.
12. Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJP. Familial hypercholesterolaemia in children. Curr Opin Lipidol 2004; 15: 405-11.
13. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S9-S17.
14. Hamilton-Craig I. Case-finding for familial hypercholesterolemia in the Asia-Pacific region. Semin Vasc Med 2004; 4: 87-92.
15. Scientific Steering Committee, Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-12.
16. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J 2008; 337: a2423.
17. Neil A, Cooper J, Betteridge J et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625-33.
18. Oosterveer DM, Versmissen J, Schinkel AF, Langendonk JG, Mulder M, Sijbrands EJ. Clinical and genetic factors influencing cardiovascular risk in patients with familial hypercholesterolemia. Clin Lipidol 2010; 5: 189-97.
19. World Health Organization. Familial Hypercholesterolaemia. Report of A Second WHO Consultation. Geneva: World Health Organization, 1999.
20. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen M-R et al. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32: 1769-818.
21. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol 2008; 19: 362-8.
22. Descamps OS, Tenoutasse S, Stephenne X et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011; 218: 272-80.
23. Starr B, Hadfield G, Hutton BA et al. Development of sensitive and specific age-and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008; 46: 791-803.
24. Maxwell SJ, Molster CM, Poke SJ, O'leary P. Communicating familial hypercholesterolemia genetic information within families. Gen Test Mol Bioma 2009; 13: 301-6.
25. von Wagner C, Steptoe A, Wolf MS, Wardle J. Health literacy and health actions: a review and a framework from health psychology. Health Educ Behav 2009; 36: 860-77.
26. Aatre RD, Day SM. Psychological issues in genetic testing for inherited cardiovascular diseases. Circ Cardiovasc Genet 2011; 4: 81-90.
27. Claassen L, Henneman L, Kindt I, Marteau TM, Timmermans DRM. Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia. J Health Psychol 2010; 15: 33-43.
28. Burke W, Emery J. Genetics education for primary-care providers. Nat Rev Genet 2002; 3: 561-6.
29. Greco KE, Salveson C. Identifying genetics and genomics nursing competencies common among published recommendations. J Nurs Educ 2009; 48: 557-65.
30. Dunstan D, Zimmet P, Welborn T et al. Diabesity & Associated Disorders in Australia - 2000: The Accelerating Epidemic. The Australian Diabetes, Obesity and Lifestyle Study. Melbourne: International Diabetes Institute, 2001.
31. Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-55.
32. National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high bloodcholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
33. Tonkin A, Barter P, Best J et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management - 2005. Heart Lung Circ 2005; 14: 275-91.
34. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-414.
35. Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk. Diabetes Care. 2008; 31: 811-22.
36. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
37. Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. Br Med J 2009; 338: b2376.
38. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
39. de Jongh S, Lilien MR, op't Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2117-21.
40. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
41. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc 1990; 264: 3007-12.
42. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S18-S29.
43. Alonso R, Fernandez de Bobadilla J, Mendez I, Lazaro P, Mata N. Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy. Rev Esp Cardiol 2008; 61: 382-93.
44. Nherera L, Calvert NW, DeMott K et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010; 26: 529-36.
45. Avis HJ, Vissers MN, Stein EA et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.
46. Arambepola C, Farmer AJ, Perera R, Neil HAW. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 2007; 195: 339-47.
47. Vuorio A, Kuoppala J, Kovanen PT et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010; (7): CD006401.
48. Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S30-S7.
49. Kusters DM, Homsma SJM, Hutten BA et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. Neth J Med 2010; 68: 299-303.
50. Simons LA, Oritz M, Calcino G. Long term persistence with statin therapy: experience in Australia 2006-2010. Aust Fam Physician 2011; 40: 319-22.
51. Dawood OT, Izham M, Ibrahim M, Palaian S. Medication compliance among children. World J Pediatr. 2010; 6: 200-2.
52. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126: 314-45.
53. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011; 97: 350-6.
54. Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345-61.
55. De Sauvage Nolting PRW, Defesche JC, Buirma RJA, Hutten BA, Lansberg PJ, Kastelein JJP. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003; 253: 161-8.
56. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
57. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53. Epub October 21.
58. Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6.
59. Burton H, Alberg C, Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services. A Needs Assessment and Service Review. Cambridge, UK: PHG Foundation, 2009. Accessed 5 April 2011. Available from: http://www.phgfoundation.org/ reports/4986/
60. Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010; 122: 2748-64.
61. Dogan S, Duivenvoorden R, Grobbee DE et al. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010; 42: 447-64.
62. Thorogood M, Seed M, De Mott K, Guideline Development Group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. Br J Obstet Gynaecol 2009; 116: 478-9.
63. Pedersen KMV, Humphries SE, Roughton M, Besford JS. The national audit of the management of familial hypercholesterolaemia 2010: full report. Clinical Standards Department, Royal College of Physicians. December 2010. Accessed 30 December 2010. Available from: http://www.rcplondon.ac.uk/node/ 2584
64. Aarden E, Van Hoyweghen I, Horstman K. The paradox of public health genomics: definition and diagnosis of familial hypercholesterolaemia in three European countries. Scand J Public Health 2011; 39: 634-9.
65. Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S46-S51.
66. World Health Organization. Building blocks for action innovative care for chronic conditions: global report. 2002.
67. Oliva J, López-Bastida J, Moreno SG, Mata P, Alonso R. Costeffectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia. Rev Esp Cardiol 2009; 62: 57-65.
68. Wonderling D, Umans-Eckenhausen MAW, Marks D, Defesche JC, Kastelein JJP, Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolaemia in the Netherlands. Semin Vasc Med 2004; 4: 97-104.
69. Marang-van de Mheen PJ, ten Asbroek AHA, Bonneux L, Bonsel GJ, Klazinga NS. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the Netherlands. Eur Heart J 2002; 23: 1922-30.
70. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000; 4: 1-123.
71. Nherera L, Marks D, Minhas R, Thorogood M, Humphries SE. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011; 97: 1175-81.
72. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. Br Med J 2002; 324: 1303-9.
73. Marks D, Thorogood M, Neil HAW, Wonderling D, Humphries SE. Comparing costs and benefits over a 10 year period for strategies for familial hypercholesterolaemia screening. J Public Health Med 2003; 25: 47-52.
74. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care 2005; 21: 240-5.
75. Goldman L, Goldman PA, Williams LW, Weinstein MC. Costeffectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993; 72: D75-D9.
76. Watts GF, Lewis B, Sullivan DR. Familial hypercholesterolaemia: a missed opportunity in preventive medicine. Nat Clin Pract Cardiovasc Med 2007; 4: 404-5